Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 10/20 | 0.74 |
| ▸ | HDAC3 | O15379 | 9/20 | 0.74 |
| ▸ | HDAC2 | Q92769 | 8/20 | 0.74 |
| ▸ | HDAC4 | P56524 | 5/20 | 0.74 |
| ▸ | HDAC7 | Q8WUI4 | 5/20 | 0.74 |
| ▸ | HDAC10 | Q969S8 | 5/20 | 0.74 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.74 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.74 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.74 |
| ▸ | HDAC9 | Q9UKV0 | 5/20 | 0.74 |
| ▸ | HDAC5 | Q9UQL6 | 5/20 | 0.74 |
| ▸ | NAAA | Q02083 | 2/20 | 0.68 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.60 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.60 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.60 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.56 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11220445 | 1.00 | HDAC1 (0.74) | HDAC1HDAC3HDAC2HDAC4HDAC7 | |
| SCHEMBL28444240 | 1.00 | HDAC1 (0.74) | HDAC1HDAC3HDAC2HDAC4HDAC7 | |
| SCHEMBL10600882 | 1.00 | HDAC1 (0.74) | HDAC1HDAC3HDAC2HDAC4HDAC7 | |
| SCHEMBL9099931 | 1.00 | HDAC1 (0.74) | HDAC1HDAC3HDAC2HDAC4HDAC7 | |
| SCHEMBL6358652 | 0.94 | HDAC3 (0.74) | HDAC1HDAC3HDAC2HDAC4HDAC7 | |
| SCHEMBL12422572 | 0.88 | HDAC1 (0.74) | HDAC1HDAC3HDAC2HDAC4HDAC7 | |
| SCHEMBL6360257 | 0.88 | HDAC3 (0.72) | HDAC1HDAC3HDAC2HDAC4HDAC7 | |
| SCHEMBL31047577 | 0.87 | NAAA (0.62) | HDAC1HDAC3HDAC2HDAC4HDAC7 | |
| SCHEMBL31047582 | 0.87 | NAAA (0.62) | HDAC1HDAC3HDAC2HDAC4HDAC7 | |
| SCHEMBL31047583 | 0.86 | L3MBTL1 (0.58) | HDAC1HDAC3HDAC2HDAC4HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115557849-A | Method for synthesizing imide compound under induction of NBS and water by visible light | 西南大学 | 2023-01-03 | — | — | CN | disclosed |
| WO-2014121036-A1 | 5-DEUTERO-2,4-THIAZOLIDINEDIONE AND 5-DEUTERO-2,4-OXAZOLIDINEDIONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | DEUTERX, LLC (US) | 2014-08-07 | — | — | WO | disclosed |
| US-20140221369-A1 | 5-DEUTERO-2,4-THIAZOLIDINEDIONE AND 5-DEUTERO-2,4-OXAZOLIDINEDIONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | DEUTERX, LLC (US) | 2014-08-07 | — | — | US | disclosed |
| EP-1167366-B1 | AMINE DERIVATIVES | DAIICHI SANKYO CO LTD (JP) | 2010-05-05 | — | — | EP | disclosed |
| US-7199139-B2 | Medicinal compositions containing diuretic and insulin resistance-improving agent | SANKYO COMPANY, LIMITED (JP) | 2007-04-03 | — | — | US | disclosed |
| EP-1354602-B1 | MEDICINAL COMPOSITIONS CONTAINING DIURETIC AND INSULIN RESISTANCE-IMPROVING AGENT | SANKYO CO (JP) | 2006-10-04 | — | — | EP | disclosed |
| EP-1695716-A2 | Medicinal compositions containing diuretics and insulin sensitizers | Sankyo Company, Limited (JP) | 2006-08-30 | — | — | EP | disclosed |
| CN-1255386-C | Substituted fused heterocyclic compound | SANKYO CO (JP) | 2006-05-10 | — | — | CN | disclosed |
| US-20050288339-A1 | Medicinal compositions containing diuretic and insulin resistance-improving agent | SANKYO COMPANY, LIMITED (JP) | 2005-12-29 | — | — | US | disclosed |
| CN-1208323-C | Alpha-substituted carboxylic acid derivatives | SANKYO CO (JP) | 2005-06-29 | — | — | CN | disclosed |
| US-6562849-B1 | Amine compound or pharmacologically acceptable salt thereof. These compounds are useful in the treatment and/or prophylaxis of diseases such as diabetes, hyperlipemia, arteriosclerosis, cancer, etc. | SANKYO COMPANY, LIMITED (JP) | 2003-05-13 | — | — | US | disclosed |
| US-20030078426-A1 | Amine derivative compounds | SANKYO COMPANY, LIMITED (JP) | 2003-04-24 | — | — | US | disclosed |
| US-20030069294-A1 | Alpha-substituted carboxylic acid derivatives | SANKYO COMPANY, LIMITED (JP) | 2003-04-10 | — | — | US | disclosed |
| US-6432993-B1 | BENZIMIDAZOLE OR IMIDAZO(4,5-B)PYRIDINE DERIVATES; IMMUNOMODULATORS; ALDOSE REDUCTASE AND LIPOXYGENASE INHIBITORS; DIABETES; PREVENTS LIPID PEROXIDATION; ANTILIPEMIC, HYPOTENSIVE AGENTS | SANKYO COMPANY, LIMITED (JP) | 2002-08-13 | — | — | US | disclosed |
| CN-1354750-A | Amine derivatives compounds | SANKYO CO (JP) | 2002-06-19 | — | — | CN | disclosed |
| CN-1353694-A | Alpha-substituted carboxylic acid derivatives | SANKYO CO (JP) | 2002-06-12 | — | — | CN | disclosed |
| EP-1167366-A1 | AMINE DERIVATIVES | Sankyo Company, Limited (JP) | 2002-01-02 | — | — | EP | disclosed |
| EP-1167357-A1 | ALPHA-SUBSTITUTED CARBOXYLIC ACID DERIVATIVES | Sankyo Company, Limited (JP) | 2002-01-02 | — | — | EP | disclosed |
| CN-1280570-A | Substituted fused heterocyclic compounds | SANKYO CO (JP) | 2001-01-17 | — | — | CN | disclosed |
| EP-1022272-A1 | SUBSTITUTED FUSED HETEROCYCLIC COMPOUNDS | Sankyo Company Limited (JP) | 2000-07-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221369-A1 | 5-DEUTERO-2,4-THIAZOLIDINEDIONE AND 5-DEUTERO-2,4-OXAZOLIDINEDIONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | SRD5A2, PPARD, SRD5A1 | HDAC1 765/4885HDAC3 266/4885HDAC2 560/4885 |
| US-20030069294-A1 | Alpha-substituted carboxylic acid derivatives | SLC5A1, SLC2A1, GPR119 | HDAC1 326/4885HDAC3 346/4885HDAC2 701/4885 |
| US-20050288339-A1 | Medicinal compositions containing diuretic and insulin resistance-improving agent | GPR119, INSR, IRS1 | HDAC1 1286/4885HDAC3 889/4885HDAC2 3429/4885 |
| US-20030078426-A1 | Amine derivative compounds | H1-10, APOB, PRMT1 | HDAC1 90/4885HDAC3 201/4885HDAC2 199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.